Source comparison
Quickcomparison
Dose Range Kisspeptin-10 50–100 mcg PT-141 (Bremelanotide) 1.75–2 mg Frequency Once daily As needed Administration Subcutaneous injection Cycle Length 4-6 weeks Ongoing/indefinite Onset Speed Rapid (hours to days) Evidence Level Moderate human trials (Phase 1-
This comparison does not assign a generated winner or score.
- Dose Range
- Kisspeptin-10
- 50–100 mcg
- PT-141 (Bremelanotide)
- 1.75–2 mg
- Frequency
- Once daily
- As needed
- Administration
- Subcutaneous injection
- Cycle Length
- 4-6 weeks
- Ongoing/indefinite
- Onset Speed
- Rapid (hours to days)
- Evidence Level
- Moderate human trials (Phase 1-2)
- Strong human trials (Phase 3 or FDA approved)
- Efficacy